Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Rev Epidemiol Sante Publique ; 61(5): 485-92, 2013 Oct.
Artigo em Francês | MEDLINE | ID: mdl-23993690

RESUMO

BACKGROUND: In 1994, the French health care system established a special status for certain costly drugs reimbursed for ambulatory use: exception drugs. Drugs with this status are reimbursed only when prescribed for specified indications. The purpose of this study was to identify the specific characteristics of drugs with the exception status, and to understand the role of this status in proper use of drugs. METHODS: Drugs included in the study were analyzed using three types of data: administrative, clinical and economic. RESULTS: For most of the drugs, prescription was restrictive. For five of them, the sickness fund accepted reimbursements for fewer indications than mentioned in the marketing authorisation. For the majority, reimbursement was 100%. The exception drugs were indicated for the treatment of 15 diseases. Eighty percent of expenditures for exception drugs concerned ten drugs. CONCLUSION: The characteristics considered in the study did not enable a specific description of the inherent features of exception drugs. This special status was established for the purpose of economic efficiency. Currently, its role in ensuring proper use of drugs is questionable.


Assuntos
Prescrições de Medicamentos/normas , Uso de Medicamentos/normas , Prescrições de Medicamentos/economia , Reposicionamento de Medicamentos/economia , Reposicionamento de Medicamentos/normas , Uso de Medicamentos/economia , Uso de Medicamentos/legislação & jurisprudência , Revisão de Uso de Medicamentos , França , Custos de Cuidados de Saúde , Humanos , Seguro , Legislação de Medicamentos , Produção de Droga sem Interesse Comercial/economia , Mecanismo de Reembolso
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...